Moat
82.0/10
Recurring diagnostics, proprietary consumables, reference labs, instrument placements, and software integrations create high switching costs for clinics.
IDXXQueued from the May 25, 2026 S&P 500 market-cap snapshot ranks 201-225; refreshed with public company, product, market-data, and open-source references reviewed on 2026-06-02.
IDEXX Laboratories
IDEXX Laboratories provides veterinary diagnostics, practice software, reference-lab services, and water, livestock, poultry, and dairy testing products.
Metadata
Where this company sits
- Ticker
- IDXX
- Rank snapshot
- ≈ 225
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Region
- United States
- Index
- S&P 500 · Top 225 by market cap
Metrics
Scoring view
Every metric is paired with a short rationale. The numbers are deliberate, not divine.
Decentralizability
34.0/10
Practice software and lab information workflows are decentralizable, but validated diagnostics, reagents, analyzers, clinical trust, and quality systems remain hard to replicate locally.
Profitability
86.0/10
The 2025 Form 10-K reported $1.06 billion of net income on $4.30 billion of revenue, indicating strong profitability for a diagnostics and software platform.
Price / Earnings
42.0x
Using a May 2026 market capitalization near $44.12 billion and 2025 net income of about $1.06 billion implies a trailing P/E near 42.
Market cap
$44.1B
CompaniesMarketCap reported IDEXX's market capitalization at about $44.12 billion as of May 2026.
Freed-up capital potential
$0.0
Derived from market cap, moat resistance, decentralizability, and profitability. It is a directional estimate of value capture that could come under pressure if open alternatives compound.
IPO market cap
$14.0M
IDEXX's investor FAQ says the company went public on June 21, 1991, offering 1,600,000 shares; CB Insights reports the IPO round amount as $14 million.
IPO return multiplier
3,151.4x
Current market cap divided by the IPO market cap implied on 1991-06-21.
Yearly market cap growth since IPO
25.9%
Compound annual market cap growth from the IPO date 1991-06-21 through the snapshot date 2026-06-02.
Narrative
Why the company matters
A short editorial overview plus the current thesis on moat strength and decentralization pressure.
Business mix
IDEXX is centered on companion-animal diagnostics, combining in-clinic instruments, SNAP rapid-assay kits, reference laboratories, imaging, and veterinary software.
Its smaller Water and Livestock, Poultry and Dairy segments extend the same testing and quality-control pattern into environmental and production-animal markets.
Operating model
The company benefits from recurring diagnostic consumables, reference-lab volume, integrated software workflows, and a large installed base of veterinary clinics.
Its 2025 Form 10-K reported $4.30 billion of revenue and $1.06 billion of net income, with the Companion Animal Group representing the great majority of revenue.
Moat reading
IDEXX's moat is strongest where hardware, consumables, reference-lab workflows, test menus, practice-management software, and clinic habits reinforce each other. A clinic that uses IDEXX analyzers, VetLab connectivity, SNAP tests, and Cornerstone has operational switching costs that go beyond simple product substitution.
The moat is not absolute: veterinary practices can choose other software and diagnostic vendors, and open-source lab and practice-management software can pressure software lock-in. The proprietary diagnostics stack, regulatory expectations, clinical validation requirements, and brand trust still make rapid decentralization difficult.
Decentralization reading
The software layer is the most decentralizable part of IDEXX's footprint because appointment, invoicing, medical-record, inventory, and lab-order workflows can be implemented by open systems if practices accept migration friction and integration gaps.
The diagnostic-kit layer is harder to decentralize because assay performance, quality control, reagents, clinical validation, and liability matter. Open laboratory information systems, open microscopy hardware, and local manufacturing can still erode parts of the stack around data capture, workflow routing, and low-cost screening.
Products
Where the moat actually touches users
These pages zoom into the products and services that matter most to each company, the alternatives already nibbling at them, and 4 structured disruption concepts across the current product set.
4 disruption concepts tracked0 documented exceptions
SNAP tests
Veterinary rapid diagnostics
2 conceptsSNAP tests are IDEXX rapid-assay kits used by veterinary clinics for point-of-care screening of companion-animal diseases and health conditions.
Cornerstone software
Veterinary practice management software
2 conceptsCornerstone is IDEXX's server-based veterinary practice management software for scheduling, medical records, inventory, invoicing, diagnostics integration, and clinic workflows.
Technology waves
Strategic lenses
These are the repo's explicit bias terms: the technologies expected to keep making incumbents less inevitable over time.
Microfactories and automated mini-home production
Small, software-defined manufacturing cells could make localized production less eccentric and more default.
- • Products with heavy branding but generic bill-of-materials profiles look increasingly vulnerable.
- • Logistics moats still matter, but their margin for arrogance should narrow.
- • Open-source production recipes can pressure both price and product differentiation.
Printed electronics and PCB tooling
PCB fabrication, chip packaging, and increasingly automated electronics assembly continue shrinking the distance between prototype and local production.
- • Incumbents with hardware lock-in should be evaluated against a future of much cheaper custom electronics.
- • Pick-and-place automation lowers the coordination cost for distributed manufacturing cells.
- • The most durable hardware moats may migrate toward fabs, ecosystems, and compliance rather than assembly itself.
Paper trail
Visible evidence trail
These sources shaped the scoring and writing. The site is opinionated, but it should not behave like it is improvising facts in a dark room.
IDEXX Laboratories 2025 Form 10-K
U.S. Securities and Exchange Commission · annual report
Primary filing for IDEXX business description, product categories, segments, revenue, net income, and risk context.
Reviewed 2026-06-02
IDEXX Products and Services
IDEXX Laboratories · product page
Company product overview covering SNAP tests, in-house diagnostics, practice software, and other business lines.
Reviewed 2026-06-02
Cornerstone Veterinary Software
IDEXX Laboratories · product page
Product page describing Cornerstone's practice-management features and diagnostic integrations.
Reviewed 2026-06-02
IDEXX Laboratories Market Capitalization
CompaniesMarketCap · market data
Market capitalization reference for IDEXX around the S&P 500 snapshot period.
Reviewed 2026-06-02